Condition

Autoimmune Diseases of the Nervous System

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting4
Common interventions25
Lead sponsors shown12
Advertisement

Clinical trials

14 shown
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNCT07759115 · 2026-08-10
RECRUITING
Biomarkers in Autoimmune Disease of Nervous SystemNCT06502015 · 2024-07-31
RECRUITING
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSNCT05834855 · 2023-04-01
RECRUITING
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemNCT04561557 · 2020-09-22
RECRUITING
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDED
Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility StudyNCT05792176 · 2023-03-27
COMPLETED
Acceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple SclerosisNCT04786821 · 2022-06-23
COMPLETED
Aerobic Exercise for Remyelination in Multiple SclerosisNCT04539002 · 2021-04-29
COMPLETED
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or NatalizumabNCT04837651 · 2021-03-02
COMPLETED
Power Training in Older Multiple Sclerosis PatientsNCT04762342 · 2020-12-07
UNKNOWN
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisNCT03540485 · 2019-11-29
TERMINATED
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisNCT01453764 · 2016-04-01
WITHDRAWN
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple SclerosisNCT01684761 · 2012-08-01
COMPLETED
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple SclerosisNCT01056471 · 2010-01-01
COMPLETED

Common interventions

Leading sponsors

Trial status mix

COMPLETED6
RECRUITING4
SUSPENDED1
TERMINATED1
UNKNOWN1
WITHDRAWN1

Phase mix

NA6
PHASE13
PHASE23
EARLY_PHASE11
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.